Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ASH 2018

1 - 4 Dec 2018
San Diego Convention Center, San Diego, United States of America
Characterisation of novel subtypes in B progenitor acute lymphoblastic leukaemia
Dr Zhaohui Gu - St. Jude Children's Research Hospital, Memphis, USA
Characterisation of novel subtypes in B progenitor acute lymphoblastic leukaemia ( Dr Zhaohui Gu - St. Jude Children's Research Hospital, Memphis, USA )
19 Dec 2018
Bispecific CD19/22 CAR therapy in children and young adults with ALL
Dr Liora M Schultz - Stanford University, Palo Alto, USA
Bispecific CD19/22 CAR therapy in children and young adults with ALL ( Dr Liora M Schultz - Stanford University, Palo Alto, USA )
17 Dec 2018
Checkpoint blockade therapy may sensitise non-Hodgkin lymphoma to subsequent the...
Dr Nicole Carreau - NYU Langone Health, New York, USA
Checkpoint blockade therapy may sensitise non-Hodgkin lymphoma to subsequent therapy ( Dr Nicole Carreau - NYU Langone Health, New York, USA )
17 Dec 2018
Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone i...
Dr Mark Bustoros - Harvard Medical School, Boston, USA
Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smouldering multiple myeloma ( Dr Mark Bustoros -  Harvard Medical School, Boston, USA )
17 Dec 2018
Indoximod combined with chemotherapy in newly diagnosed AML patients
Dr Ashkan Emadi - University of Maryland Medical Centre, Maryland, USA
Indoximod combined with chemotherapy in newly diagnosed AML patients ( Dr Ashkan Emadi - University of Maryland Medical Centre, Maryland, USA )
17 Dec 2018
Combined ibrutinib and venetoclax in patients with treatment-naïve high-risk CLL
Dr Nitin Jain - MD Anderson Cancer Centre, Houston, USA
Combined ibrutinib and venetoclax in patients with treatment-naïve high-risk CLL ( Dr Nitin Jain - MD Anderson Cancer Centre, Houston, USA )
17 Dec 2018
CAR-T cell dosing approaches in treating acute lymphoblastic leukaemia
Prof Bijal Shah - H. Lee Moffitt Cancer Centre & Research Institute, Tampa, USA
CAR-T cell dosing approaches in treating acute lymphoblastic leukaemia ( Prof Bijal Shah - H. Lee Moffitt Cancer Centre & Research Institute, Tampa, USA )
17 Dec 2018
Phase II trial of nivolumab combined with ibrutinib for patients with Richter tr...
Dr Nitin Jain - MD Anderson Cancer Centre, Houston, USA
Phase II trial of nivolumab combined with ibrutinib for patients with Richter transformation ( Dr Nitin Jain - MD Anderson Cancer Centre, Houston, USA )
17 Dec 2018
Ibrutinib with obinutuzumab in patients with chronic lymphocytic leukaemia
Dr Carolina Moreno Atanasio - Hospital de la Santa Creu i Sant Pau, Barcelona, S...
Ibrutinib with obinutuzumab in patients with chronic lymphocytic leukaemia ( Dr Carolina Moreno Atanasio - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )
17 Dec 2018
Results of using dara-CyBorD to treat patients with newly diagnosed or relapsed ...
Dr Habte Yimer - Texas Oncology, Tyler, USA
Results of using dara-CyBorD to treat patients with newly diagnosed or relapsed multiple myeloma ( Dr Habte Yimer - Texas Oncology, Tyler, USA )
17 Dec 2018
Blinatumomab as second salvage therapy in adults with relapsed/refractory aggres...
Prof Alessandro Rambaldi - University of Milan, Milan, Italy
Blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-NHL ( Prof Alessandro Rambaldi - University of Milan, Milan, Italy )
13 Dec 2018
Efficacy and safety of KRd or KCd induction in multiple myeloma
Dr Francesca Gay - University of Torino, Torino, Italy
Efficacy and safety of KRd or KCd induction in multiple myeloma ( Dr Francesca Gay - University of Torino, Torino, Italy )
13 Dec 2018
Maintenance therapy with the oral PI ixazomib significantly prolongs PFS followi...
Dr Francesca Gay - University of Torino, Torino, Italy
Maintenance therapy with the oral PI ixazomib significantly prolongs PFS following ASCT in multiple myeloma ( Dr Francesca Gay - University of Torino, Torino, Italy )
13 Dec 2018
Results from the EMN-011 trial, combination therapy for multiple myeloma
Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands
Results from the EMN-011 trial, combination therapy for multiple myeloma ( Prof Pieter Sonneveld -  Erasmus MC Cancer Institute, Rotterdam, Netherlands )
13 Dec 2018
Cytotoxic T lymphocyte cell therapy for post-transplant lymphoproliferative diso...
Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
Cytotoxic T lymphocyte cell therapy for post-transplant lymphoproliferative disorder in the central nervous system ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )
13 Dec 2018
Clinical impact of an accurate genetic characterisation of older AML patients
Prof Alessandro Rambaldi - University of Milan, Milan, Italy
Clinical impact of an accurate genetic characterisation of older AML patients ( Prof Alessandro Rambaldi - University of Milan, Milan, Italy )
13 Dec 2018
Two clinical trials using combination therapy in adult patients with multiple my...
Dr Irene M. Ghobrial - Dana-Farber Cancer Institute, Boston, USA
Two clinical trials using combination therapy in adult patients with multiple myeloma ( Dr Irene M. Ghobrial - Dana-Farber Cancer Institute, Boston, USA )
12 Dec 2018
The combined analysis of carfilzomib trials for multiple myeloma
Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain
The combined analysis of carfilzomib trials for multiple myeloma ( Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain )
7 Dec 2018
Gilteritinib combined with induction and consolidation chemotherapy in newly dia...
Dr Keith Pratz - Johns Hopkins University, Baltimore, USA
Gilteritinib combined with induction and consolidation chemotherapy in newly diagnosed AML patients ( Dr Keith Pratz - Johns Hopkins University, Baltimore, USA )
6 Dec 2018
Axicabtagene Ciloleucel in patients with refractory large B Cell lymphoma
Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA
Axicabtagene Ciloleucel in patients with refractory large B Cell lymphoma ( Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA )
6 Dec 2018
Matched targeted therapy for paediatric patients with relapsed, refractory or hi...
Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA
Matched targeted therapy for paediatric patients with relapsed, refractory or high-risk leukemias ( Dr Yana Pikman - Dana Farber Cancer Institute, Boston, USA )
6 Dec 2018
Alpha/beta T-cell and B-cell depletion haplo-HSCT is an effective treatment for ...
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
Alpha/beta T-cell and B-cell depletion haplo-HSCT is an effective treatment for children with acute leukaemia ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
6 Dec 2018
Results from RIALTO, blinatumomab for paediatric patients with B-cell precursor ...
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
Results from RIALTO, blinatumomab for paediatric patients with B-cell precursor relapsed/refractory ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
6 Dec 2018
ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline t...
Dr Lorenz Trümper - Georg August University, Göttingen, Germany
ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with T-Cell lymphomas ( Dr Lorenz Trümper - Georg August University, Göttingen, Germany )
6 Dec 2018
AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed/r...
Prof Marion Subklewe - University of Munich, Munich, Germany
AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed/refractory AML ( Prof Marion Subklewe - University of Munich, Munich, Germany )
6 Dec 2018
KRd versus VRd in patients with newly diagnosed multiple myeloma
Dr Ola Landgren - Memorial Sloan Kettering Cancer Centre, New York, USA
KRd versus VRd in patients with newly diagnosed multiple myeloma ( Dr Ola Landgren -  Memorial Sloan Kettering Cancer Centre, New York, USA )
6 Dec 2018
Researchers identify mutation that causes resistance to venetoclax in CLL patien...
Dr Piers Blombery - University of Melbourne, Melbourne, Australia
Researchers identify mutation that causes resistance to venetoclax in CLL patients ( Dr Piers Blombery - University of Melbourne, Melbourne, Australia )
6 Dec 2018
Daratumumab increases PFS in patients with transplant-ineligible multiple myelom...
Prof Thierry Facon - Hôpital Claude Huriez, Lille, France
Daratumumab increases PFS in patients with transplant-ineligible multiple myeloma ( Prof Thierry Facon - Hôpital Claude Huriez, Lille, France )
6 Dec 2018
Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger...
Dr Tait Shanafelt - Standford University, Stanford, USA
Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL ( Dr Tait Shanafelt - Standford University, Stanford, USA )
6 Dec 2018
Resistance mechanisms to venetoclax in patients with progressive CLL
Dr Piers Blombery - University of Melbourne, Melbourne, Australia
Resistance mechanisms to venetoclax in patients with progressive CLL ( Dr Piers Blombery - University of Melbourne, Melbourne, Australia )
4 Dec 2018
Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy
Dr Alok Khorana - Cleveland Clinic, Cleveland, USA
Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy ( Dr Alok Khorana - Cleveland Clinic, Cleveland, USA )
4 Dec 2018
Ibrutinib-based therapy superior for younger patients with previously untreated ...
Dr Tait Shanafelt - Stanford University, Stanford, USA
Ibrutinib-based therapy superior for younger patients with previously untreated CLL compared with current standard of care ( Dr Tait Shanafelt - Stanford University, Stanford, USA )
4 Dec 2018
Daratumumab found to increase PFS in patients with transplant-ineligible newly d...
Prof Thierry Facon - Hôpital Claude Huriez, Lille, France
Daratumumab found to increase PFS in patients with transplant-ineligible newly diagnosed multiple myeloma ( Prof Thierry Facon - Hôpital Claude Huriez, Lille, France )
4 Dec 2018
Patient treatment preferences in relapsed/refractory multiple myeloma
Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos
Patient treatment preferences in relapsed/refractory multiple myeloma ( Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos )
3 Dec 2018
Landscape change with oral proteasome maintenance in multiple myeloma patients
Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar Lo...
Landscape change with oral proteasome maintenance in multiple myeloma patients ( Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar Lonial )
3 Dec 2018
The importance of NF-kB pathway in myeloma
Dr Nizar Bahlis - University of Calgary, Calgary, Canada
The importance of NF-kB pathway in myeloma ( Dr Nizar Bahlis - University of Calgary, Calgary, Canada )
3 Dec 2018
Multiple myeloma highlights and more from ASH 2018
Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
Multiple myeloma highlights and more from ASH 2018 ( Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France )
3 Dec 2018
Results of the Beat AML umbrella study for previously untreated acute myeloid le...
Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA
Results of the Beat AML umbrella study for previously untreated acute myeloid leukaemia ( Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA )
3 Dec 2018
An integrated view of the role of the B cell antigen receptor in lymphoma cell f...
Dr Stefano Casola - Institute of Molecular Oncology Foundation, Milan, Italy
An integrated view of the role of the B cell antigen receptor in lymphoma cell fitness ( Dr Stefano Casola - Institute of Molecular Oncology Foundation, Milan, Italy )
3 Dec 2018
Myeloma XI study: Quadruplet regimen for transplant eligible patients
Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK
Myeloma XI study: Quadruplet regimen for transplant eligible patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )
3 Dec 2018
Developments in CAR T treatments for adult patients
Dr David Miklos - Stanford University, Palo Alto, USA
Developments in CAR T treatments for adult patients ( Dr David Miklos - Stanford University, Palo Alto, USA )
3 Dec 2018
Outcomes for patients with disease progression following CD19-specific CAR T-cel...
Dr Victor Chow - Fred Hutchinson Cancer Research Centre, Seattle, USA
Outcomes for patients with disease progression following CD19-specific CAR T-cell therapy ( Dr Victor Chow - Fred Hutchinson Cancer Research Centre, Seattle, USA )
3 Dec 2018
ASH 2018: Expert overview of the latest in CLL, ALL and AML
Prof Robin Foa - University of Rome, Rome, Italy
ASH 2018: Expert overview of the latest in CLL, ALL and AML ( Prof Robin Foa - University of Rome, Rome, Italy )
3 Dec 2018
Updates on the ELIANA trial for acute lymphocytic leukaemia in young patients
Dr Stephan Grupp - Children's Hospital of Philadelphia, Philadelphia, USA
Updates on the ELIANA trial for acute lymphocytic leukaemia in young patients ( Dr Stephan Grupp - Children's Hospital of Philadelphia, Philadelphia, USA )
2 Dec 2018
Determining the prognosis of patients with myelodysplastic syndromes using machi...
Dr Aziz Nazha - Cleveland Clinic, Cleveland, USA
Determining the prognosis of patients with myelodysplastic syndromes using machine learning ( Dr Aziz Nazha - Cleveland Clinic, Cleveland, USA )
2 Dec 2018
Long term data from JULIET trial, using tisagenlecleucel for patients with relap...
Dr Richard Maziarz - Oregon Health & Science Knight Cancer Institute, Portland, ...
Long term data from JULIET trial, using tisagenlecleucel for patients with relapsed or treatment-resistant DLBCL ( Dr Richard Maziarz - Oregon Health & Science Knight Cancer Institute, Portland, USA )
2 Dec 2018
The benefits of a stem cell transplant after CAR T-cell therapy in paediatric pa...
Dr Corinne Summers - Seattle Children's Hospital, Seattle, USA
The benefits of a stem cell transplant after CAR T-cell therapy in paediatric patients ( Dr Corinne Summers - Seattle Children's Hospital, Seattle, USA )
2 Dec 2018
ECHELON-2: a large peripheral T-cell lymphoma trial
Dr Owen O'Connor - Columbia University Medical Centre, New York, USA
ECHELON-2: a large peripheral T-cell lymphoma trial ( Dr Owen O'Connor - Columbia University Medical Centre, New York, USA )
2 Dec 2018
ACT-1: Addition of alemtuzumab to a CHOP backbone for young patients with T-cell...
Dr Owen O'Connor - Columbia University Medical Centre, New York, USA
ACT-1: Addition of alemtuzumab to a CHOP backbone for young patients with T-cell lymphoma ( Dr Owen O'Connor - Columbia University Medical Centre, New York, USA )
2 Dec 2018
Link between gut microbiota and haematopoietic cell transplantation outcomes
Dr Jonathan Peled - Memorial Sloan Kettering Cancer Centre, New York, USA
Link between gut microbiota and haematopoietic cell transplantation outcomes ( Dr Jonathan Peled -  Memorial Sloan Kettering Cancer Centre, New York, USA )
2 Dec 2018
Initial report of the Beat AML umbrella study for previously untreated AML
Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA
Initial report of the Beat AML umbrella study for previously untreated AML ( Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA )
2 Dec 2018
Machine learning algorithm improves prognosis accuracy for patients with myelody...
Dr Aziz Nazha - Cleveland Clinic, Cleveland, USA
Machine learning algorithm improves prognosis accuracy for patients with myelodysplastic syndromes ( Dr Aziz Nazha - Cleveland Clinic, Cleveland, USA )
2 Dec 2018
Diversity of gut microbiota linked with complications from haematopoietic cell t...
Dr Jonathan Peled - Memorial Sloan Kettering Cancer Centre, New York, USA
Diversity of gut microbiota linked with complications from haematopoietic cell transplantation ( Dr Jonathan Peled -  Memorial Sloan Kettering Cancer Centre, New York, USA )
2 Dec 2018
Progression-free survival milestones in primary central nervous system lymphoma
Dr Jorne Lionel Biccler - Aalborg University, Aalborg, Denmark
Progression-free survival milestones in primary central nervous system lymphoma ( Dr Jorne Lionel Biccler - Aalborg University, Aalborg, Denmark )
2 Dec 2018
Relapse risk and loss in expectation of lifetime in young classical hodgkin lymp...
Dr Jorne Lionel Biccler - Aalborg University, Aalborg, Denmark
Relapse risk and loss in expectation of lifetime in young classical hodgkin lymphoma patients ( Dr Jorne Lionel Biccler - Aalborg University, Aalborg, Denmark )
2 Dec 2018
New therapies for transfusion dependent MDS patients
Dr Alan List - Moffitt Cancer Centre, Tampa, USA
New therapies for transfusion dependent MDS patients ( Dr Alan List - Moffitt Cancer Centre, Tampa, USA )
2 Dec 2018
Reduction of chemotherapy cycles for diffuse large B-cell lymphoma
Dr Viola Pöschel - Saarland University Medical School, Homburg, Germany
Reduction of chemotherapy cycles for diffuse large B-cell lymphoma ( Dr Viola Pöschel - Saarland University Medical School, Homburg, Germany )
1 Dec 2018
Inhibiting the immune system’s natural response may boost benefits and sustainab...
Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA
Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy ( Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA )
1 Dec 2018
Ibrutinib alone and in combination with rituximab for older patients with chroni...
Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Centre, Colu...
Ibrutinib alone and in combination with rituximab for older patients with chronic lymphocytic leukaemia ( Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Centre, Columbus, USA )
1 Dec 2018
Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell ...
Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA
Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell therapy for relapsed and/or refractory CLL ( Dr Jordan Gauthier  - Fred Hutchinson Cancer Research Centre, Seattle, USA )
1 Dec 2018
Latest analysis of the ELIANA trial for acute lymphocytic leukaemia
Dr Stephan Grupp - University of Pennsylvania, Philadelphia, USA
Latest analysis of the ELIANA trial for acute lymphocytic leukaemia ( Dr Stephan Grupp - University of Pennsylvania, Philadelphia, USA )
1 Dec 2018
CD19-directed CAR T-cell therapy for patients with relapsed B-cell acute lymphoc...
Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA
CD19-directed CAR T-cell therapy for patients with relapsed B-cell acute lymphocytic leukaemia ( Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA )
1 Dec 2018
Latest results from JULIET: Tisagenlecleucel in adults with DLBCL
Dr Richard Maziarz - Oregon Health & Science Knight Cancer Institute, Portland, ...
Latest results from JULIET: Tisagenlecleucel in adults with DLBCL ( Dr Richard Maziarz - Oregon Health & Science Knight Cancer Institute, Portland, USA )
1 Dec 2018
CAR T-Cell therapy with concurrent ibrutinib for chronic lymphocytic leukaemia
Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA
CAR T-Cell therapy with concurrent ibrutinib for chronic lymphocytic leukaemia ( Dr Jordan Gauthier  - Fred Hutchinson Cancer Research Centre, Seattle, USA )
1 Dec 2018
Stem cell transplant after CAR T-cell therapy reduces relapses in acute lymphocy...
Dr Corinne Summers - Seattle Children's Hospital, Seattle, USA
Stem cell transplant after CAR T-cell therapy reduces relapses in acute lymphocytic leukaemia ( Dr Corinne Summers - Seattle Children's Hospital, Seattle, USA )
1 Dec 2018
Four cycles of chemotherapy as effective as six for diffuse large B-Cell lymphom...
Dr Viola Pöschel - Saarland University Medical School, Homburg, Germany
Four cycles of chemotherapy as effective as six for diffuse large B-Cell lymphoma ( Dr Viola Pöschel - Saarland University Medical School, Homburg, Germany )
1 Dec 2018
Luspatercept reduces need for blood transfusions in beta thalassemia and MDS
Dr Maria Domenica Cappellini - University of Milan, Milan, Italy
Luspatercept reduces need for blood transfusions in beta thalassemia and MDS ( Dr Maria Domenica Cappellini - University of Milan, Milan, Italy )
1 Dec 2018
Ibrutinib outperforms chemoimmunotherapy in older patients with chronic lymphocy...
Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Center, Colu...
Ibrutinib outperforms chemoimmunotherapy in older patients with chronic lymphocytic leukaemia ( Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Center, Columbus, USA )
1 Dec 2018
Results from the MEDALIST trial for patients with anaemia in MDS
Dr Alan List - Moffitt Cancer Center, Tampa, USA
Results from the MEDALIST trial for patients with anaemia in MDS ( Dr Alan List - Moffitt Cancer Center, Tampa, USA )
1 Dec 2018